Zacks Investment Research downgraded shares of Ritter Pharmaceuticals (NASDAQ:RTTR) from a hold rating to a sell rating in a research report sent to investors on Thursday.
According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “
Separately, ValuEngine upgraded Ritter Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Ritter Pharmaceuticals presently has a consensus rating of Hold and an average price target of $2.10.
An institutional investor recently bought a new position in Ritter Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned 4.49% of Ritter Pharmaceuticals as of its most recent SEC filing. 20.34% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3255880/ritter-pharmaceuticals-rttr-downgraded-to-sell-at-zacks-investment-research.html.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.